Biomet acquires all assets of Cytosol Laboratories

Biomet, Inc., a global leader in the manufacture of musculoskeletal medical products, announced today its acquisition of substantially all of the assets of Cytosol Laboratories, Inc., located in Braintree, Massachusetts, a market leader in production of small volume anticoagulants.

“This acquisition solidifies a critical supply component utilized by our market-leading GPS® III Platelet Separation System and BioCue™ Platelet Concentration System for concentrating a mixture of blood and bone marrow”

Cytosol was founded in 1968 to develop anticoagulants and other products to aid in the processing of blood components. The company has three proprietary products with New Drug Application approvals: TriCitrasol^®, noClot-50^™ and Rejuvesol^®. TriCitrasol^® is used for anticoagulation during granulocytapheresis while Rejuvesol^® is used for the rejuvenation of stored, frozen red blood cells prior to transfusion.

"This acquisition solidifies a critical supply component utilized by our market-leading GPS^® III Platelet Separation System and BioCue^™ Platelet Concentration System for concentrating a mixture of blood and bone marrow," said Stuart Kleopfer, President of Biomet Biologics. Mr. Kleopfer continued, "In addition, given the increased scrutiny of stored red blood cells and increasing attention being paid by clinicians to the benefits of granulocytapheresis, both of these products have excellent market potential. We welcome the Cytosol team and are eager to explore additional indications for this unique product line."